Charles River achieves 92% renewable energy use

ESG

Charles River Laboratories has reported achieving 92% renewable energy usage worldwide in its 2023 Corporate Citizenship Report.

The 2023 report evaluates the company’s progress across its strategic Environmental, Social and Governance (ESG) areas of focus: Accelerate Life-Saving Therapies; Lead with Integrity; Inspire our People; and Protect our Planet.

“The work we do at Charles River today extends beyond science. With more than 21,000 employees, our collective efforts are powerful, and our influence is transforming the biopharmaceutical industry to make a difference for both patients and the planet,” said James Foster, Chair, President, and Chief Executive Officer of Charles River.

The report states that Charles River worked on 80% of the drugs approved by the US Food and Drug Administration (FDA) in the past five years (2019-2023) and 85% of the drugs approved by the FDA in 2023 alone.

Other highlights include:

  • During the 2022-2023 period, the company established a Responsible Animal Use Committee of the company’s Board of Directors and the Office for Responsible Animal Usage (ORAU) to oversee responsible animal utilisation and reduction practices, and operating standards of care.
  • Charles River advanced women in leadership, with women representing 53% of total leadership in 2023 and the composition of women at the Executive Leadership level (VP+) increasing to 42% in 2023.
  • The company contributed a record total of 29,000 employee volunteer hours in 2023.
  • The company reported a reduction of Scope 1 and 2 global greenhouse gas (GHG) emissions by 37% over the last five years, targeting a 50% reduction by 2030.
  • It achieved 92% renewable electricity usage globally, working toward the deployment of 100% renewable electricity across operations by 2030.
  • The annual Sustainability Capital Fund, originally introduced in 2020, supported $13.5 million in projects by the end of 2023.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free